Abstract
Tweetable abstract Severe COVID-19 patients display dysregulated expression of checkpoint molecules PD-1 and its ligand PD-L1, suggesting that these checkpoint molecules could be considered as prognostic markers and therapeutic targets in severe cases of COVID-19.
Keywords: COVID-19; PD-1; PD-L1; SARS-CoV-2; adaptive immune cells; immune checkpoint molecules; innate immune cells.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, PD-1, PD-L1, adaptive immune cells, immune checkpoint molecules, innate immune cells., 【초록키워드】 adaptive, Prognostic markers, immune, PD-1, PD-L1, severe cases, Prognostic marker, immune cells, Innate immune cells, expression, therapeutic targets, Ligand, COVID-19 patient, therapeutic target, Abstract, Severe case, dysregulated, 【제목키워드】 role,
【저자키워드】 COVID-19, SARS-CoV-2, PD-1, PD-L1, adaptive immune cells, immune checkpoint molecules, innate immune cells., 【초록키워드】 adaptive, Prognostic markers, immune, PD-1, PD-L1, severe cases, Prognostic marker, immune cells, Innate immune cells, expression, therapeutic targets, Ligand, COVID-19 patient, therapeutic target, Abstract, Severe case, dysregulated, 【제목키워드】 role,
{{{ 추상적인 }}}
중증 COVID-19 환자는 체크포인트 분자 PD-1과 그 리간드 PD-L1의 조절되지 않은 발현을 보이며, 이는 이러한 체크포인트 분자가 COVID-19의 중증 사례에서 예후 마커 및 치료 표적으로 간주될 수 있음을 시사합니다.
{{ 키워드: }} 코로나19; PD-1; PD-L1; 사스 코로나바이러스 2; 적응 면역 세포; 면역 체크포인트 분자; 선천 면역 세포.